Nolvadex Articles
Wal-Mart expands drug program to 90 days
12 May 2008
Reverse payment ban stalls in US Congress
19 November 2007
Cytogen's 4th-qtr 2006 losses up 85.4%
12 March 2007
US Supreme Court backs Barr in tamoxifen antitrust suit
7 February 2007
Japan's generic drugs market expected to grow 8.8% from 2006 to 2008
27 November 2006
Cytogen's 3rd-qtr 2006 net loss improves 24%
13 November 2006
75% of cancer drugs "available on Medicare"
2 October 2006
Cytogen to distribute Soltamox in USA
1 May 2006
Savient in German marketing deal for Soltamox
10 January 2005
UK NHS to offer free IVF treatment
1 March 2004
AstraZeneca forecasts sharp rise in earnings but shares slip on mediocre Crestor sales
9 February 2004
AstraZeneca 4th-qtr results lower, but in line with expectations
2 February 2004
AstraZeneca raises full-year earnings guidance
28 July 2003
IVAX gets US go-ahead for generic Nolvadex
3 March 2003
Nolvadex to carry new warning on US label
8 July 2002
AstraZeneca files in EU for new Arimidex use
15 April 2002
Barr second-quarter earnings leap on sales of generic Prozac
4 February 2002
Arimidex fast-tracked for early breast cancer.
21 January 2002
FDA warns AstraZeneca and DuPont about ads.
21 January 2002
Arimidex outdoes tamoxifen in study
13 December 2001
Arimidex and tamoxifen compatible in breast cancer
19 September 2001
Barr's entitlement to tamoxifen exclusivity questioned
29 August 2001
Consumer groups sue S-P over Claritin claims
15 August 2001
Barr Labs increases earnings estimate
12 July 2001
Barr acquires Duramed - UPDATE
2 July 2001
Schering-Plough, etc sued over K-Dur20
11 June 2001
Celgene drug promises activity in solid tumors
8 June 2001
US consumer groups in court over generics
11 May 2001
AstraZeneca hit by slip in Losec sales
26 April 2001
AstraZeneca files for Faslodex in USA
30 March 2001
Informa Pharma Award winners
21 March 2001
AstraZeneca set for Arimidex extension
26 February 2001
Barr Labs sees last qtr 2000 earnings up 33%
16 February 2001
AstraZeneca issues sales and profits slowdown warning
8 February 2001
Novartis R&D day updates prospects for key pipeline drugs
7 December 2000
Pharmacia reveals new anticancer results
16 October 2000
Novartis shows tamoxifen superiority with breast cancer drug Femara
29 September 2000
AstraZeneca retains US patent on Nolvadex
20 September 2000
Tamoxifen study argues for caution regarding use in healthy women
12 September 2000
First-line approval for AstraZeneca's Arimidex
4 September 2000
"Greed vs need" in US brand/generic deals
26 July 2000
Nolvadex is first drug approved for DCIS
5 July 2000
Shire's Fareston shows equivalence to tamoxifen
25 May 2000
AstraZeneca sees 17% 1st qtr pretax growth
3 May 2000
AstraZeneca gets expanded labeling for Arimidex
13 April 2000
AstraZeneca full-year profits up 20% as new products come good
24 February 2000
US launch for P&U's Aromasin
27 January 2000
AstraZeneca's tamoxifen, effective in older women
19 January 2000
R-PR gets FDA panel OK for Taxotere use
15 December 1999
First comparitive trial shows benefit of AstraZeneca's Arimidex over
13 December 1999
Raloxifene approval hots up osteoporosis treatment market
11 October 1999
Arimidex hailed as tamoxifen successor
16 September 1999
Lilly ordered to stop false claims for Evista
22 July 1999
NASBP study highlights tamoxifen triple therapy
16 June 1999
STAR trial gets underway
26 May 1999
Targretin effective in tamoxifen resistance
13 April 1999
FDA confirms Barr Laboratories' generic tamoxifen right
11 March 1999
Zeneca shows confidence on Astra merger; reports good 1998 results
17 February 1999
Osteoporosis Drug Evista Halves Breast Cancer Risk
16 December 1998
GW, SB Lining Up Offers For Zeneca?
15 December 1998
Osteoporosis Drug Evista Halves Breast Cancer Risk
14 December 1998
Zeneca Receives FDA Warning Letter For Misleading Advertisments
3 December 1998
Nolvadex Approval Puts Zeneca On A High
19 November 1998
Stock Commentary Europe
5 November 1998
Zeneca's Nolvadex Approval From US FDA
2 November 1998
Zeneca's Nolvadex Recommended To FDA
3 September 1998
Zeneca Updates Its R&D Pipeline
6 August 1998
Zeneca Profits Decline, But Underlying Growth Strong
6 August 1998
US Advisory Panel Meetings
22 July 1998
Stock Commentary Europe
16 July 1998
New Studies Cast Doubt On Tamoxifen As Preventive
14 July 1998
UK Pharma Leaders Outline Strategy
22 June 1998
Raloxifene Efficacy In Breast Cancer
21 May 1998
New York Stock Comment
21 May 1998
Nolvadex Filed For Breast Cancer Prevention
5 May 1998
Stock Commentary Europe
16 April 1998
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
